StreetAlpha.app
Home › Stocks › BVS

Bioventus Inc. (BVS)

Healthcare
$9.88
▼ −0.70%
LAST CLOSE · NOV 20

Bioventus makes pain treatment and surgical products for musculoskeletal care, sold to physicians, surgeons and hospitals. It last closed at $9.88 on Nov 20, down 0.70% on the day. The next earnings report for BVS is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, BVS reported EPS of $0.08 on revenue of $142.4M, with revenue up 2.7% from a year ago. Over its last 8 reports the stock moved an average of 13.6% the session after earnings. Over the last 12 months BVS insiders bought $0 of stock on the open market and sold $181K, according to SEC Form 4 filings.

AI Auto Pilots
Is BVS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BVS.

Key Stats

Last 12 months
Results
Revenue
$585.6M
+3.9% vs a year ago
Net income
$57.3M
+655.0% vs a year ago
EPS (diluted)
$0.81
+575.0% vs a year ago
Free cash flow
$85.0M
14.5% margin
Balance sheet
Cash & equivalents
$30.7M
At Sep 26
Debt
$229.8M
At Sep 26
Shareholder equity
$240.5M
Employees960 (Sep 26, 2026)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $430.9M$430.9MFY2021FY2022: $512.1M$512.1MFY2022FY2023: $512.3M$512.3MFY2023FY2024: $573.3M$573.3MFY2024FY2025: $568.1M$568.1MFY2025

From BVS's SEC filings, latest 10-Q for the period ending Sep 26, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · Time not announced
Reported EPS
$0.08
Quarter ended Sep 2026
Year ago EPS
$0.05
+60.0% on a GAAP basis
Revenue
$142.4M
+2.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.00Dec '24Mar 2025: -$0.04Mar '25Jun 2025: $0.11Jun '25Sep 2025: $0.05Sep '25Dec 2025: $0.21Dec '25Mar 2026: $0.04Mar '26Jun 2026: $0.47Jun '26Sep 2026: $0.08Sep '26Latest $0.08
Revenue by quarter
Dec 2024: $153.6MDec '24Mar 2025: $123.9MMar '25Jun 2025: $147.7MJun '25Sep 2025: $138.7MSep '25Dec 2025: $157.9MDec '25Mar 2026: $132.1MMar '26Jun 2026: $153.2MJun '26Sep 2026: $142.4MSep '26Latest $142.4M
How BVS moved after its last 8 reports
Average move the session after a report ±13.6%
Nov 2, 2026After the close−16.8%
Aug 5, 2026Time not announced+13.7%
May 6, 2026Time not announced+2.3%
Mar 5, 2026Time not announced+7.4%
Nov 4, 2025Time not announced+15.1%
Aug 6, 2025Time not announced+18.7%
May 6, 2025Time not announced−11.8%
Mar 11, 2025Time not announced+23.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BVSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BVS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BVS

Technical Analysis

BVS · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 19% below its 20 day and 30% below its 50 day average. It is 13% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the Pivot S1 at $9.74, and the nearest resistance the Pivot at $9.95.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 6.4%/day
Key levels
$15.8952 week high+60.8%
$12.99100 day average+31.5%
$12.8150 day average+29.7%
$12.30Swing high (Jul 9)+24.5%
$11.7520 day average+18.9%
$11.12200 day average+12.6%
$10.10Pivot R1+2.2%
$9.95Pivot+0.7%
$9.88Last close
$9.74Pivot S1−1.4%
$9.28Swing low (Jun 30)−6.1%
$6.4752 week low−34.5%
Indicators
RSI (14)28.91Oversold below 30Oversold
MACD-0.89Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)30.8Trending down
Williams %R-96.7Oversold below −80, overbought above −20Oversold
CCI (20)-82.9Oversold below −100, overbought above 100Neutral
Rate of change−6.9%Change over 10 sessionsBearish
ATR (14)$0.63Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BVS

What happened before

See how BVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BVS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BVSHow many large options trades hit BVS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BVS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲93 buying vs 74 selling
  • ●Shares held by funds -0.6%
  • ▲Funds holding +13
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding170157+8.3%
In funds' top 10330.0%
Held by funds–––
New / increased35 / 5824 / 76−7.0%
Reduced / sold out49 / 2537 / 23+23.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BVS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BVS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$181K2 sales · 2 insiders
2025-12 sold $76K2026-03 sold $105KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 11Michelle McMurry-HeathDirectorSale12,000$8.79$105K
Dec 4, 2025Guy P NohraDirectorSale10,000$7.57$76K
Nov 7, 2025Michelle McMurry-HeathDirectorSale17,701$7.42$131K
Apr 11, 2025Katrina J ChurchSVP & Chief Compliance OfficerSale plan1,283$7.57$10K
Apr 11, 2025Anthony D'AdamioSVP & General CounselSale plan2,958$7.57$22K
Apr 11, 2025Mark Leonard SingletonSVP & CFOSale plan3,875$7.57$29K
Every insider buy and sale for BVS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BVS insider trades →

From SEC Form 4 filings by BVS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BVS is in one of them and how their past BVS trades turned out.

BVS in the AI portfolios
Loading…

BVS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BVS in an article yet. Here's the latest on the wider market.

BVS in the news

About Bioventus

Bioventus is a medical device company based in Durham, North Carolina. It makes products that relieve pain and treat musculoskeletal conditions, including hyaluronic acid knee injections, implantable nerve stimulation systems for chronic pain, and ultrasonic bone cutting tools used in spine and neurosurgery. The company also offers bone graft substitutes that support bone fusion and a device that uses low intensity pulse ultrasound to help fractures heal. Its customers include physicians and surgeons, along with the hospitals, clinics and ambulatory surgical centers where patients are treated.

Headquarters
Durham, NC